Economics of ramucirumab for metastatic colorectal cancer-Reference-Cited by-同舟云学术

Economics of ramucirumab for metastatic colorectal cancer

Published:2016-11-01 Issue:6 Volume:16 Page:733-745
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Zeichner Simon B.¹,Kohn Christine G.²,Goldstein Daniel A.¹³

Affiliation:

1. Division of Hematology & Oncology, Winship Cancer Institute at Emory University, Atlanta, GA, USA

2. Hartford Hospital Evidence-Based Practice Center, University of Saint Joseph School of Pharmacy & UConn, Hartford, CT, USA

3. Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2016.1259070

Reference102 articles.

1. Cancer statistics, 2015

2. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

3. Ramucirumab mCRC. U.S. Food and Drug Administration. cited 2016 Jun 20. Available form: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm444496.htm.

4. NCCN Guidelines: Colon cancer. Version 2.2016. cited 2016 May 12. Available from: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Nurse–Pharmacist Collaborative Approach to Reducing Financial Toxicity in Cancer Care;Clinical Journal of Oncology Nursing;2022-01-25

2. Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era;International Journal of Molecular Sciences;2021-07-19

3. Risk–benefit Analysis of FOLFIRI Plus Ramucirumab/Aflibercept as a Third-line Treatment in Metastatic Colorectal Cancer;Anticancer Research;2021-06

4. Risk Benefit of FOLFIRI Plus Ramucirumab as Third-line and Later-line Treatment of Metastatic Colorectal Cancer;Anticancer Research;2020-03

5. Cost-effectiveness analysis of ramucirumab treatment for patients with hepatocellular carcinoma who progressed on sorafenib with α-fetoprotein concentrations of at least 400 ng/ml;Journal of Medical Economics;2020-01-06